**Hypercalcemia in Dogs and Cats**

**Profile**

**Definitions**
- Hypercalcemia is defined as either an elevation of total serum calcium (tCa) or ionized calcium (iCa) above physiologically normal homeostatic levels.
  - In dogs, tCa above 12.0 mg/dl or iCa above 1.5 mmol/L qualifies as hypercalcemia.
  - In cats, tCa above 11.0 mg/dl or iCa above 1.4 mmol/L qualifies as hypercalcemia.
- Elevated iCa can affect multiple organs, resulting in altered cell membrane permeability and subsequent disturbances in biological functions of the nervous, gastrointestinal, cardiac, and renal systems.
- Causes of hypercalcemia are diverse, but may be categorized into several subgroups differentiated by severity and underlying cause.
  - Nonpathologic increases in serum calcium are often incidental findings and do not result in clinical signs classically associated with severe elevations in calcium. Causes accounting for nonpathologic hypercalcemia include:
    - Mobilization of calcium secondary to skeletal growth, most commonly observed in young large- to giant-breed dogs
    - Lipemic serum samples resulting in spurious elevations in calcium.
  - Increases in serum calcium may be transient, often resulting from significant but reversible dehydration or relative increases in intravascular protein concentrations, especially albumin.

**Pathophysiology**

Although many causes of elevated calcium levels are benign, hypercalcemia is usually associated with some underlying disease process. Pathologic hypercalcemia may be categorized as parathyroid hormone (PTH)-dependent or independent as follows:
- **PTH-dependent conditions**—primary hyperparathyroidism results in excessive production of PTH, resulting in elevated iCa.
  - Neoplastic
    - Adenoma (common)
    - Functional adenocarcinoma (rare)
  - Nonneoplastic
    - Hyperplasia (rare)
- **PTH-independent conditions**—Many diseases that induce elevations in calcium are not dependent on the production and secretion of PTH per se, but cause hypercalcemia via alternative mechanisms.
  - Cancer-related
    - Humoral hypercalcemia of cancer occurs when cancer cells liberate a peptide that is structurally similar to endogenous PTH, called PTH-related peptide (PTH-rp).
      - Lymphoma (most common form in dogs): anatomical location—mediastinal (common), immunophenotype—T cell (common)
      - Anal sac apocrine gland adenocarcinoma (second most common form in dogs): tumors cause elevations in calcium through the secretion of PTH-rp

Cytologic sample of an anal sac mass identified upon rectal examination in a 4-year-old, spayed female dalmatian with history of straining to defecate and acute-onset polyuria and polydipsia. Diagnosis of hypercalcemia of malignancy secondary to PTH-related peptide production from apocrine gland anal sac adenocarcinoma was the final diagnosis.

continues
Various types of epithelial cancer (carcinomas): mammary, thyroid, adrenal, pancreatic, pulmonary, nasal, thymic epithelial, bronchogenic (feline), oral squamous cell (feline)

- Pathologic elevations of calcium may result from focal or diffuse skeletal osteolysis, whereby direct destruction of the bone matrix by invading tumor cells or associated cytokines results in calcium release. The following types of cancer have been identified to or theoretically could cause hypercalcemia via this described mechanism: T-cell lymphoma; acute lymphoblastic leukemia; multiple myeloma (common); solitary osseous plasma cell tumor; and primary bone sarcomas (rare) including osteosarcoma, fibrosarcoma, chondrosarcoma, and hemangiosarcoma.

- In very rare instances, hypercalcemia mediated by elevations in PTH-rp has been associated with infectious disease, including that caused by *Heterobilharzia americana* (dog).

Pathologic hypercalcemia may also result from disorders associated with granulomatous processes. Mechanistically, hypercalcemia is mediated by macrophage dysregulation of 1α-hydroxylase activity, resulting in excessive conversion of cholecalciferol to highly active 1,25-(OH)₂cholecalciferol (calcitriol). Granulomatous diseases documented to be associated with hypercalcemia include the following:

- *Angiostrongylus vasorum* (dog)
- Atypical mycobacterium (feline)
- *Blastomyces dermatitidis* (dog)
- *Cryptococcus neoformans* (feline)

Calcium homeostasis is a complex process orchestrated by an interaction among 3 principal mediators (PTH, calcitonin, and calcitriol) and their target organs (bone matrix, renal tubules, and intestine). Hypercalcemia may result from any one or a combination of the following derangements:

- **PTH- or PTH-rp–mediated hypercalcemia**—physiologic consequences of elevated PTH or PTH-rp include:
  - Enhanced calcium reabsorption from the distal tubules
  - Enhanced conversion of calcitriol in the proximal tubules, resulting in greater intestinal resorption of calcium
  - Enhanced osteoclast maturation and activity resulting in greater bone resorption activities.

- **Calcitriol-mediated hypercalcemia**—

An invasive soft tissue mass involving the glossal frenulum of a 13-year-old, castrated male domestic shorthair. Screening blood analysis identified pathologic elevations in serum calcium. Histopathologic evaluation of the mass confirmed oral squamous cell carcinoma.

Cranial mediastinal mass identified on thoracic radiographs from a 10-year-old, male castrated golden retriever presenting for hypercalcemia. Upon fine-needle aspiration and cytologic evaluation, the mass effect was confirmed to be T-cell lymphoma.

High-detail cervical spinal radiograph of an 8-year-old spayed female, mixed-breed dog, initially presenting for severe neck pain and moderate hypercalcemia. Multiple purely lytic bone lesions are observed throughout the vertebrae and were confirmed to be plasma cell cancer (multiple myeloma).
physiologic consequences of elevated active vitamin D₃ includes:

- Enhanced intestinal resorption of calcium
- Synergism with PTH to enhance osteoclast maturation and activity resulting in greater bone resorption.

**Causes/Risk/Factors**

- Hypercalcemia may result from ingestion of toxin containing vitamin D or its active metabolites and has been documented for the following poisons:
  - Plants that contain calcitriol glycosides (day blooming jessamine)
  - Rodenticides containing cholecalciferol
  - Ingestion of antipsoriasis creams containing calcipotriol or calcipotriene.

- Miscellaneous causes of hypercalcemia account for a diverse group of processes that cause elevations in $tCa$ or $iCa$. For the most part, the mechanisms of hypercalcemia associated with these disorders remain poorly defined and include the following:
  - Idiopathic hypercalcemia (the most common cause of elevated $iCa$ in cats). Most patients do not have any clinical signs.
  - Chronic renal failure. Associated with elevated $tCa$ but rarely $iCa$.
  - Nonneoplastic skeletal disorders. Such disorders as bacterial or fungal osteomyelitis can also result in elevations in calcium.

**Clinical Signs**

Clinical signs associated with pathologic calcium elevations are related to the magnitude of hypercalcemia as well as the rate of elevation. Generally, clinical signs are more pronounced in patients with acute onset of severe hypercalcemia and include the following:

- Nervous system
  - Lethargy and weakness (common)
  - Neuromuscular twitching (rare)
  - Seizures
- Gastrointestinal tract
  - Anorexia
  - Vomiting
  - Diarrhea or constipation (rare)
- Cardiac system
  - Weakness or collapse
  - Narrow QT and prolonged PR intervals
  - Arrhythmias (rare)
- Renal system
  - Polyuria and polydipsia
  - Dehydration and prerenal azotemia
  - Renal insufficiency
  - Calcium urolithiasis

**Diagnostic Tests**

Suggested diagnostic tests to identify causes of hypercalcemia in dogs and cats are listed in Table 1.

**Treatment**

The urgency for managing hypercalcemia depends on the underlying cause as well as the severity and duration of calcium elevations. The intent of therapy targeting clinical signs is to reverse the deleterious effects of high $iCa$ levels on organ function.

- Identification of the underlying cause for hypercalcemia is paramount but should not supersede the immediate supportive care necessary to sustaining and maintain a critically ill patient.
- The following supportive care should be instituted immediately:
  - Vigorous rehydration with isotonic saline (0.9% sodium chloride) or lactated Ringer’s solution. Isotonic saline is preferred but not essential—lactated Ringer’s solution is a viable option for intravascular volume restoration.
  - Amount recommended for adequate volume expansion is 100

$iCa = $ ionized calcium, $PTH = $ parathyroid hormone, $PTH-rp = $ parathyroid-hormone–related peptide, $tCa = $ total calcium

---

A 5-year-old, castrated male dachshund presenting for chronic lameness, draining cutaneous lesions, and mild hypercalcemia. The radiograph demonstrates a mixed lytic/blastic process involving the distal aspects of the antebrachium (A). Cytologic evaluation of the pathologic bone identified a thick-walled budding organism consistent with *Blastomyces dermatitidis* (B).
• Recommended furosemide dosage:
  **Intermittent pulse therapy:** 2–4 mg/kg Q 8–12 H IV, SC, or PO
  **Continuous-rate infusion:** 0.66 mg/kg loading dose followed by a constant-rate infusion of 0.66 mg/kg/hr (equivalent to 5–6 mg/kg Q 8 H)

- Sodium bicarbonate (although rarely used) is effective for rapidly reducing iCa levels and should be considered for severely compromised patients.
  - Recommended sodium bicarbonate dosage: 1 mEq/kg IV slow bolus

- Injectable aminobisphosphonates, such as pamidronate, have been shown to be safe and effective for treating dogs and cats with hypercalcemia.
  - Recommended pamidronate dosage:
    - In cases of vitamin D toxicosis in dogs—1.3–2.0 mg/kg IV over 20 minutes or 2 hours
    - In cats for management of hypercalcemia—1.0–1.5 mg/kg IV over 2 hours

- Calcitonin plays only a minor role in calcium regulation but can reduce serum calcium levels by reducing osteoclast activity and formation and has been used effectively for managing vitamin D toxicosis in dogs.
  - Recommended calcitonin dosages:
    - 4–6 IU/kg SC Q 8–12 H

- Glucocorticoids should be avoided unless a definitive diagnosis has been made, as hypercalcemia secondary to lymphoma is the most common cause of elevated calcium levels in dogs and administration of glucocorticoids before diagnosis of lymphoma can confound or preclude a definitive diagnosis.
  - Recommended glucocorticoid dosages:
    - **Prednisone:** 1.0–2.2 mg/kg Q 12 H IV, SC, or PO
    - **Dexamethasone:** 0.1–0.22 mg/kg Q 12 H IV, SC, or PO

<table>
<thead>
<tr>
<th>Method of Diagnosis</th>
<th>Possible Findings and Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Exposure to vitamin D–related toxin; excessive dietary supplementation of calcium or vitamin D</td>
</tr>
<tr>
<td>Physical examination</td>
<td>Caudal displacement of heart sounds could suggest mediastinal mass effect</td>
</tr>
<tr>
<td>Rectal examination</td>
<td>Palpate sacral lymph nodes, anal sacs, and prostate gland for evidence of mass effects or pathologic enlargements</td>
</tr>
<tr>
<td>Fundic examination</td>
<td>Fungal granuloma, retinal hemorrhage, or detached retina (hyperglobulinemia secondary to multiple myeloma)</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>Abnormal circulating cells</td>
</tr>
<tr>
<td>Serum biochemistry</td>
<td>Total calcium, phosphorus, blood urea nitrogen, and creatinine (chronic renal failure)</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Low specific gravity (chronic renal failure)</td>
</tr>
<tr>
<td>Fecal examination</td>
<td>Rule out parasitic cause (eg, schistosomiasis)</td>
</tr>
<tr>
<td>Fine-needle aspiration and cytologic evaluation</td>
<td>Enlarged lymph node or suspect lesions (bone or soft tissue)</td>
</tr>
<tr>
<td>Chest radiography</td>
<td>Cranial mediastinal mass or other pathologic condition of lung parenchyma (cancer/fungus)</td>
</tr>
<tr>
<td>Abdominal ultrasonography</td>
<td>Look for lymphadenopathy (lymphoma, granulomatous disease, AGASACA*); observe spleen and liver to evaluate for lymphoma; observe prostate for mass effects, pathologic enlargement, or areas of mineralization</td>
</tr>
<tr>
<td>Corticotropin-stimulation test</td>
<td>Confirmation of hypoadrenocorticism</td>
</tr>
<tr>
<td>Ionized calcium</td>
<td>Confirmation of true hypercalcemia</td>
</tr>
<tr>
<td>PTH/PTH-rp</td>
<td>Primary hyperparathyroidism or humoral hypercalcemia of cancer</td>
</tr>
<tr>
<td>Serum calcitriol</td>
<td>Vitamin D toxicosis or granulomatous disease</td>
</tr>
<tr>
<td>Bone survey/bone scan</td>
<td>Look for lytic lesions (multiple myeloma or mixed lytic and blastic cells in carcinomas)</td>
</tr>
<tr>
<td>Ultrasoundography of ventral cervical area</td>
<td>Enlarged parathyroid gland (primary hyperparathyroidism)</td>
</tr>
<tr>
<td>Bone marrow cytologic evaluation</td>
<td>Identification of malignant lymphoma or plasma cells (multiple myeloma)</td>
</tr>
<tr>
<td>Protein electrophoresis</td>
<td>Monoclonal or biclonal gammopathy with lymphoma and multiple myeloma</td>
</tr>
</tbody>
</table>

*Apocrine gland anal sac adenocarcinoma
Follow-Up

Patient Monitoring
The intensity and frequency of monitoring hypercalcemia is dictated by the clinical severity of disease. Recommended monitoring in critically ill patients may include the following:
• Repeat iCa measurements Q 12 to 24 H with therapeutic adjustments as indicated
• Precautions: monitor serum electrolytes in addition to calcium. Aggressive fluid diuresis and loop diuretics may result in hypokalemia.

Course:
• Provide adequate time for normalization. Patients with severe hypercalcemia will probably require several days of intensive management before hospital discharge.
• After patient stabilization:
  - Diagnose and treat underlying cause of hypercalcemia
  - Provide supportive or definitive treatment depending on the cause of hypercalcemia.

In General

Relative Cost
Management of hypercalcemia can be costly because critically ill patients require intensive hospitalization, diagnostic testing to determine the underlying cause, and treatment.
• $SSS–$SSSS (depending on disease severity and underlying cause)

Costs of therapy for managing hypercalcemic patient (30-kg dog):
• Intravenous fluid therapy with hospitalization: $–$/day
• Furosemide therapy: $/day

Cost Key
$ = < $100 $SSS = $500–1000
$SS = $100–250 $SSSS = > $1000
$SSS = $250–500

Tx at a glance

Treat underlying condition, meanwhile:
• 0.9% sodium chloride or lactated Ringer’s solution for volume expansion (100–125 mg/kg/day IV)
• After rehydration:
  - Furosemide
    - Intermittent pulse therapy—2–4 mg/kg Q 8–12 H IV, SC, PO
    - Continuous rate infusion—0.66 mg/kg loading dose; then 0.66 mg/kg/hr (~ 5–6 mg/kg Q 8 H)
  - For severely compromised patients
    - Sodium bicarbonate—1 mEq/kg IV slow bolus
  - Pamidronate
    - For vitamin D toxicosis in dogs—1.3–2.0 mg/kg IV over 20 min or 2 hr
    - In cats—1.0–1.5 mg/kg IV over 2 hr
  - Glucocorticoid
    - Prednisolone—1.0–2.2 mg/kg Q 12 H IV, SC, PO
    - Dexamethasone—0.1–0.22 mg/kg Q 12 H IV, SC, PO
  - Calcitonin—4–6 IU/kg SC Q 8–12 H

• Sodium bicarbonate: $/day
• Pamidronate: $SS–$SSS/treatment cycle (every 7–28 days)
• Calcitonin: $–$/day
• Glucocorticoids: $/day

Prognosis
• The outcome for dogs and cats diagnosed and treated for hypercalcemia varies and depends on whether long-term organ damage has occurred and the underlying disease process.
• Many diseases associated with hypercalcemia are curable or manageable with long-term therapies.

See Aids & Resources, back page, for references, contacts, and appendices.

iCa = ionized calcium, PTH = parathyroid hormone, PTH-rp = parathyroid-hormone–related peptide, Cl = chloride, K = potassium, Na = sodium